描述
Atosiban (CAS 90779-69-4) is a synthetic cyclic peptide that acts as a selective oxytocin receptor antagonist. By competitively inhibiting oxytocin binding in uterine smooth muscle, Atosiban effectively suppresses uterine contractions. It’s widely used in laboratory studies focused on delaying preterm labor, understanding labor initiation mechanisms, and exploring reproductive endocrine regulation.
Manufactured under strict GMP guidelines and offering high purity (99.23%), this peptide provides reliable performance for experimental protocols in reproductive pharmacology.
Product Specifications
Parameter | Details |
---|---|
Product Name | Atosiban |
Synonyms | (None widely used) |
CAS Number | 90779-69-4 |
Purity | 99.23% (HPLC) |
Molecular Formula | C??H??N?O?? |
Molecular Weight | ~893 Da |
Appearance | White to off-white lyophilized powder |
Solubility | Soluble in aqueous solutions and lab buffers |
Storage | –20 °C, dry and light-protected |
GMP Compliance | Yes |
Intended Use | Laboratory research use only |
Mechanism of Action & Research Applications
Atosiban competitively inhibits oxytocin receptors in the uterus, preventing oxytocin-induced muscle contraction. It alters downstream signaling by reducing intracellular calcium release and myosin phosphorylation. Key research applications include:
-
Preterm labor models: Simulating therapeutic interventions aimed at suppressing uterine overactivity.
-
Uterine physiology studies: Elucidating the roles of oxytocin receptors and uterine signaling pathways.
-
Hormonal regulation: Examining interactions between oxytocin, prostaglandins, and uterine contraction pathways.
-
In vitro contractility assays: Serving as a control in isolated smooth muscle or organ bath studies to assess contraceptive or tocolytic effects.
Side Effects (For Research Context Only)
Under controlled lab conditions, Atosiban treatment may result in:
-
Transient hypotension: Due to peripheral vasodilation in sensitive in vivo models.
-
Altered labor patterns: Studied in ex vivo perfused uterine models to assess timing and strength of contractions.
-
Feedback hormone response: Models might show increased basal oxytocin receptor expression after prolonged exposure, useful for research on receptor regulation.
-
Non-target effects: Potential effects on uterine blood flow and prostaglandin release, observed in perfusion or organ culture systems when exploring interrelated pathways.
These findings help deepen understanding of uterine contractile control and pharmacologic regulation. Always monitor dose and context-specific responses.
Disclaimer
Atosiban is strictly for laboratory research use only. It is not approved for human or veterinary therapeutic use, or for diagnosing conditions.
评价
目前还没有评价